Neuland Laboratories Limited

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 04, 2026. The meeting will consider and adopt the Audited Financial Statements for the financial year ended March 31, 2026, and the Audited Consolidated Financial Statements for the financial year ended March 31, 2026. The meeting will also consider the appointment of Dr. Mauricio Futran as Non-Executive Non-Independent Director of the Company, and the payment of commission to the Non-executive Directors of the Company.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.

Neuland Laboratories Limited

Neuland Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the equity shares of the Company shall remain closed from July 1, 2026, till 48 hours after the declaration of financial results for the quarter ended June 30, 2026.